Prostate cancer (PCa) is the second most common cancer in men.Aswell in many other human cancers, inflammation and immune
suppression have an important role in their development.We briefly describe the host components that interact with the tumor to
generate an immune suppressive environment involved in PCa promotion and progression.Different tools provide to overcome the
mechanisms of immunosuppression including vaccines and immune checkpoint blockades. With regard to this, we report results
of most recent clinical trials investigating immunotherapy in metastatic PCa (Sipuleucel-T, ipilimumab, tasquinimod, Prostvac-VF,
and GVAX) and provide possible future perspectives combining the immunotherapy to the traditional therapie
